Pharmaceuticals

NeuroVive Pharmaceutical AB Interim Report January - September 2019

STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events July - September * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July-Septem...

2019-11-20 16:38 109

Cambridge Quantum Computing Achieves Groundbreaking Results in Quantum Chemistry

CQC gets VQE "off the ground" and provides an efficient route towards simulating excited molecules using quantum computers CAMBRIDGE, England, Nov. 20, 2019 /PRNewswire/ -- Cambridge Quantum Computing ("CQC") today announced an important breakthrough in quantum chemistry that will enhance and ac...

2019-11-20 15:00 205

Merck Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations

- Japanese Ministry of Health, Labour and Welfare grants orphan drug designation for diseases that affect fewer than 50,000 patients inJapan, and for which significant unmet medical need exists - MET exon 14 (METex14) skipping alterations and MET amplifications are present in 3-5% of non-small c...

2019-11-20 15:00 255

CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib

SUZHOU, China, Nov. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the first patient has been dosed in the Phase I bridging registrational study of ivosidenib (TIBSOVO®) in China. This stand-alone trial is designed to validate the effi...

2019-11-20 11:41 222

Excelra Announces a Drug Repurposing Collaboration With Maruho On Dermatological Applications

HYDERABAD, India, Nov. 20, 2019 /PRNewswire/ -- Excelra, a leading global Data and Analytics Company today announced a Drug Repurposing collaboration withOsaka -based Maruho – a pharmaceutical company specialising in Dermatology. Under the agreement, the Drug Repurposing Data Scientists and Therap...

2019-11-20 10:00 309

3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration

SHENYANG, China and BEDFORD Mass., Nov. 17, 2019 /PRNewswire/ -- 3SBio Inc. ("3SBio") (HKEX:1530) and Verseau Therapeutics, Inc.  ("Verseau") today announced the selection of VTX-0811, a monoclonal antibody targeting PSGL-1, as the first lice...

2019-11-18 08:30 1977

BioDuro chooses SciFinder-n from CAS to enhance research productivity and shorten cycle times for client success

Collaboration between drug companies and contract research partners drives innovation in evolving business environment COLUMBUS, Ohio, Nov. 18, 2019 /PRNewswire/ -- CAS, a division of the American Chemical Society, announced today that leading contract research, development and manufacturing org...

2019-11-18 08:15 403

Unprecedented Gathering of Asia Pacific Medical Societies to Respond to the Impact of Antibiotic Resistance on All People

BANGKOK, Nov. 17, 2019 /PRNewswire/ -- In anticipation of World Antibiotic Awareness Week (18-24 November) the Antimicrobial Resistance (AMR) Summit Expert Group and the Antimicrobial Stewardship (AMS) Working Group convened in Bangkok, Thailand, in a first-ever regional effort to combat the 'sile...

2019-11-17 12:00 730

Viva Biotech Partnership Summit Successfully Launched in Shanghai

SHANGHAI, Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on8 November 2019 in Pudong, Shanghai, themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies incubated/ invested by Viva ...

2019-11-15 14:16 414

I-Mab Biopharma Receives IND Approval from NMPA to Initiate Clinical Trials for its Anti-GM-CSF Monoclonal Antibody TJM2 in China

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical-stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced that Natio...

2019-11-14 23:45 389

Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMO

INCHEON, South Korea, Nov. 14, 2019 /PRNewswire/ -- Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security management. Samsung Biologics is the first CDMO company to be ISO 27001 certified globally. A ceremony...

2019-11-14 20:00 207

MeMed Wins €2.5M Award from European Innovation Council

Funding to Accelerate Launch of MeMed's Point-of-Care Platform that Distinguishes Between Bacterial and Viral Infections,Enabling More Prompt, Well-Informed Antimicrobial Treatment Decisions HAIFA, Israel, Nov. 13, 2019 /PRNewswire/ -- MeMed Ltd. , a leader in host respo...

2019-11-14 09:00 504

China Biologic Reports Financial Results for the Third Quarter of 2019

BEIJING, Nov. 13, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the third quarter of 2019. Third Quarter...

2019-11-14 05:43 5045

Merck Licenses CRISPR Gene-Editing Technology to Evotec

-- License to accelerate research, enable testing and development of new drugs DARMSTADT, Germany, Nov. 12, 2019 /PRNewswire/ -- Merck, a leading science and technology company, today announced that it has signed a license agreement providingEvotec SE access to Merck's foundational CRISPR intelle...

2019-11-12 21:00 518

ATAI Life Sciences and Cyclica launch joint venture to revolutionize drug development for mental health disorders

BERLIN and TORONTO, Nov. 11, 2019 /PRNewswire/ -- ATAI Life Sciences AG, a global biotech platform that envisions an end to mental illnesses, andCyclica Inc., a leading biotechnology company that leverages artificial intelligence and computational biophysics to streamline the drug discovery proce...

2019-11-11 21:45 457

Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting

NATIONAL HARBOR, Md., Nov. 11, 2019 /PRNewswire/ -- Akeso Biopharma ("Akeso") presented results of phase 1 study of its first-in-class bispecific drug candidate  AK104, in patients with advanced solid tumors in 2019 Society for Immunotherapy of Cancer ("SITC"). AK104 is a novel, tetrameric bispec...

2019-11-11 17:35 246

Stone Capital Partners Biosyngen to Setup US$50 Million Biopharmaceutical Investment Fund in Singapore

SINGAPORE, Nov. 11, 2019 /PRNewswire/ -- Stone Capital and Biosyngen have partnered to establish a Biopharmaceutical Investment Fund inSingapore, the signing ceremony was held in Ascendas One Hub of Sino-Singapore Guangzhou Knowledge City. The key investment targets of the biopharmaceutical fund...

2019-11-11 10:00 306

Akeso, Inc. Completes Series-D Private Financing for US$150 Million

ZHONGSHAN, China, Nov. 9, 2019 /PRNewswire/ -- Akeso, Inc. (hereinafter referred to as "Akeso") announced the completion of its Series-D private financing for nearlyUS$150 million, which was co-led in investment by Loyal Valley Capital ("LVC") and Sino Biopharmaceutical Co. Ltd. ("Sino Biopharm")...

2019-11-09 00:43 1370

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

MADISON, Wisconsin, Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed itspreviously announced combination with Genomic Health, Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics co...

2019-11-08 21:24 5680

Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial

Not intended for US, Canada and UK-based media  DARMSTADT, Germany, and NEW YORK, Nov. 8, 2019 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction ch...

2019-11-08 21:00 4742
12345 ... 100